Printer Friendly

BioMedix Promotes Mr. David Lerner To Chief Technology Officer.

Business Editors & Health/Medical Writers

MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 20, 2001

BioMedix(R) announced the promotion of Mr. David Lerner to the BioMedix executive management team. As Chief Technology Officer, Mr. Lerner's appointment will complement the clinical and administrative expertise of existing management and represents a key milestone in the Company's strategy to accelerate implementation of bringing state-of-the-art vascular diagnostic equipment and services to a broadened marketplace.

Mr. Lerner's new responsibilities include direct management of all major technical initiatives including next generation vascular laboratories, technology based services and related accessories, managing manufacturing Quality Assurance programs for all BioMedix products and facilitating technical support for customer service.

"Filling the CTO position provides BioMedix with in-depth leadership in each of our key areas of business," states BioMedix President John Romans. "David's extensive technical and regulatory compliance background coupled with his founding knowledge of our technology makes him an ideal selection for the position and strengthens our ability to be a global leader in the delivery and support of innovative vascular diagnostic services and products."

BACKGROUND:

BioMedix manufactures, markets and sells state-of-the-art medical systems that physicians use to assess, diagnose and treat cardiovascular disease, the number one killer of adults in the United States. Founded in 1997, the Company has developed and received FDA approval for its Vascular Diagnostic Laboratory (VDL) and Portable Vascular Laboratory (PVL) systems. These BioMedix systems utilize photoplethysmography (PPG), Doppler ultrasound, blood-pressure cuffs and proprietary algorithms which assist physicians to non-invasively identify the site of and quantify the severity of vascular disease. Specifically, the BioMedix systems detect and document cardiovascular disease by characterizing arterial and venous obstruction as well as venous valvular incompetence. The BioMedix systems are also used to monitor the progress of patients with an identified circulation problem such as diabetics. All modalities of the BioMedix System are non-invasive, easy to administer, and collectively represent the most cost-effective method of diagnosing peripheral vascular disease.

For more information, visit: www.biomedix.com
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 20, 2001
Words:327
Previous Article:Cheniere Energy Announces Buy-Out of Partner and Sale of Proprietary Seismic Data Base.
Next Article:P.H. Glatfelter Company Elects Kathleen Dahlberg To Board of Directors.


Related Articles
The Creation of Feminist Consciousness: From the Middle Ages to 1870.
TRANXENOGEN SIGNS MONOCLONAL ANTIBODY DEVELOPMENT PACTS.
Security experts predict Harlem will cost Clinton more.
CHANGES IN BOARD STAFF.
LOOKING FOR ROMANTIC ENCOURAGEMENT? CAKE TOPPERS INSTILL SWEET NOTION YOU'LL BE LUCKY IN LOVE.
Fuji Biomedix to Acquire 55% Stake in Seishin Works.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters